APG 115
High-risk Myelodysplastic Syndrome
Ascentage Pharma Group Inc.Small moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the High-risk Myelodysplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan University of Birmingham | Phase 2/3 | BB |
RVU120 Ryvu Therapeutics SA | Phase 2 | B |
Vyxeos University of Birmingham | Phase 2/3 | B |
Evofosfamide Threshold Pharmaceuticals | Phase 1 | CC |
vip943 Vincerx Pharma, Inc. | Phase 1 | CC |
Cbx-250 Crossbow Therapeutics, Inc. | Phase 1 | CC |
Atrn-119 Washington University School of Medicine | Phase 1 | CC |
Same molecule, other indications
APG 115 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →